Neuroscience

#Innovation #IXICO #Neuroscience #Precision medicine #Technology

The resurgence of neuroscience

Bram Goorden, CEO, IXICO, looks at why precision medicine is the next frontier for neuroscience. For much of the early 2000s, neuroscience was one of the pharmaceutical industry’s most challenging therapeutic areas. Clinical failures accumulated and investors increasingly favoured oncology, where biomarker-driven drug development… Read More

#Exclusive Content

#Genetics #Natural killer cells #Neuroscience #Parkinson's disease #Precision medicine

Precision therapies for Parkinson’s Disease

In this contribution to the Fall 2026 issue of DDW, Dr Andrew French PhD, Dr Richard Boyd PhD, Prof Alice Pébay PhD, and Prof Alan Trounson PhD, explore emerging research into NK cell-derived extracellular vesicles (NK-EVs) as a potential therapeutic platform for neurodegenerative disease. Neurodegenerative diseases… Read More

#Exclusive Content

Neurons
#Alzheimer's #Neuroscience #Parkinson's disease #University of Queensland

UQ technology opens new front in Alzheimer’s and Parkinson’s

A technology developed at The University of Queensland allowing scientists to observe how disease-related proteins behave inside living neurons will be used to advance early drug discovery for neurodegenerative diseases.  The Nanoscale Spatiotemporal Indexing Clustering (NASTIC) platform, spun out into Brisbane-based startup Accretion Bio, enables researchers to… Read More

#News

Neurons firing
#eBook #Neurodegenerative disorders #Neurodivergence #Neuroscience

New eBook: Next-generation neuroscience drug discovery

The Neuroscience pharmaceuticals market is expected to double in size in the next ten years. An expanding elderly population means that the prevalence of neurodegenerative diseases is increasing every year and represents a significant global health burden. Neurodegenerative diseases such as Alzheimer’s disease and other dementias, Parkinson’s disease and amyotrophic… Read More

#News

Dementia
#Alzheimer's #Clinical trial #Neuroscience #UK Dementia Research Institute

New UK trial could halve the time to test Alzheimer’s drugs

A first-of-its-kind clinical trial has launched in the UK, which could cut years from the search for treatments that work for people with Alzheimer’s disease.  The national trial, called AD-SMART (Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial), is led by the UK Dementia Research Institute (UK DRI)… Read More

#Editor's Choice #News

#Advertorial #ApconiX #Central nervous system #Drug discovery #Neuroscience

Mitigating ion channel related CNS liability in novel compounds by predicting SAR

In this paid-for advertorial for the Fall 2026 issue of DDW. The ApconiX team are working towards providing a high throughput service to resolve central nervous system (CNS) liabilities earlier in the drug discovery pipeline. Their recently published study is the first reported method to use structure… Read More

#Exclusive Content

Mitochondria
#Mission Therapeutics #Neuroscience #Parkinson's #Phase I trial

Mission doses first Parkinson’s patient in Phase Ib study

Mission Therapeutics has dosed the first patient in its Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD).  MTX325 is a first-in-class, highly potent and selective, orally bioavailable and brain-penetrant inhibitor of the deubiquitinating enzyme (DUB) USP30.   It has been designed to… Read More

#News

Parkinson's disease
#Drug discovery #Lundbeck #Parkinson's

Phase Ib data in advanced Parkinson’s disease released as Phase II trial begins 

Lundbeck has announced results from an open-label Phase Ib trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist, in people with advanced Parkinson’s disease experiencing motor symptoms sub-optimally controlled despite optimised non-invasive antiparkinsonian medication.    The results are being presented at the… Read More

#News

#Genentech #License agreement #Neuroscience #Parkinson's

Genentech licenses enzyme replacement therapy for Parkinson’s

Alector has granted Genentech worldwide rights to develop and commercialise its AL050 programme, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT).  As part of the deal, Alector will receive a $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as… Read More

#Business & Investment #News

Brain physiology
#Drug development #Drug discovery #Neuroscience #Sleep disorders #Small molecules

Why sleep is the next frontier in brain health 

Michelle L. Mellion, MD, Chief Medical Officer at AstronauTx discusses why small molecules that can restore deep, restorative sleep, could be key to cognitive diseases such as Alzheimer’s.   Sleep is the bedrock of good brain health. For a long time, the focus has been on the quantity of sleep. A large body of evidence has… Read More

#Exclusive Content

Remyelination
#Financing #Multiple sclerosis #Neurology #Neuroscience #Rewind Therapeutics

New financing supports Rewind’s GPR17 remyelination programme

Rewind Therapeutics has announced additional financing to advance the development of its lead GPR17 antagonist programme, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS).  MS is characterised by damage to myelin, but there are no approved therapies… Read More

#News

Deal making
#Mergers and acquisitions #Neurodegenerative disorders #Rare disease #Shionogi

Shionogi expands rare disease portfolio with IntraBio buyout

Shionogi has announced plans to acquire IntraBio, a biopharmaceutical company developing therapies for neurodegenerative diseases, for $2 billion.  The transaction will add Aqneursa (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio.  Aqneursa was approved by the FDA in September 2024… Read More

#Business & Investment #News

Nobel prize winners Karl Deisseroth, Peter Hegemann and Georg Nagel
#Neuroscience #Nobel Prize #Optogenetics

2026 Nobel laureates “laid the foundation of a new era in neuroscience”

The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine to three scientists “for their discoveries concerning light-gated ion channels and optogenetics”.  It was jointly presented to Karl Deisseroth, The Howard Hughes Medical Institute and Stanford University, USA; Peter Hegemann, Humboldt… Read More

#Editor's Choice #News

#European Commission #European Medicines Agency #Minoryx Therapeutics #Neuraxpharm #Neurodegenerative disorders #Neuroscience

EC approves first treatment for rare neurodegenerative disease

The European Commission (EC) has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients.  It is approved in patients aged two to 12 years with Gadolinium (Gd)-negative brain lesions and is… Read More

#Editor's Choice #News #Regulatory

#Bipolar #Johnson & Johnson #Neuroscience #Phase III trial #Psychiatry

Phase III study supports lumateperone use in bipolar mania

Johnson & Johnson has announced positive topline results from a Phase III study evaluating Caplyta (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder.   The study met its primary endpoint, with Caplyta demonstrating a statistically significant and rapid… Read More

#News

Sleep study in older man
#AstronauTx #Funding #Neuroscience #Parkinson's

Grants support research into sleep mechanisms in Parkinson’s

AstronauTx has received funding from The Michael J Fox Foundation for Parkinson’s Research (MJFF), while Parkinson’s UK is funding an additional complementary research effort in collaboration with University College London (UCL).  The MJFF-funded project, titled ‘Ligand-Gated Ion Channel Modulation as a Disease-Modifying Treatment for Prodromal Synucleinopathies’, will… Read More

#News